Edition:
United States

Key Developments: Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,429JPY
2:00am EDT
Change (% chg)

¥-40 (-2.76%)
Prev Close
¥1,470
Open
¥1,480
Day's High
¥1,489
Day's Low
¥1,428
Volume
9,695,700
Avg. Vol
8,231,155
52-wk High
¥2,009
52-wk Low
¥1,358

Latest Key Developments (Source: Significant Developments)

Astellas Pharma to retire 68 mln treasury shares
Tuesday, 10 May 2016 11:05pm EDT 

Astellas Pharma Inc <4503.T>: Says it will retire 68 million shares (3.1 percent stake) of its common stock on June 20 .Says the total shares outstanding will be 2.15 billion shares after the retirement.  Full Article

Astellas to retire treasury stock equivalent to 3.06 pct of shares outstanding
Tuesday, 10 May 2016 11:03pm EDT 

Astellas Pharma Inc <4503.T>: to retire treasury stock equivalent to 3.06 percent of shares outstanding on June 20 Further company coverage: [4503.T].  Full Article

Astellas Pharma and LEO Pharma close transaction to transfer global dermatology business
Thursday, 31 Mar 2016 08:00pm EDT 

Astellas Pharma Inc:Says the company and LEO Pharma A/S completed the relevant closing conditions on March 31 to allow the transfer of the Astellas’ global dermatology business to LEO Pharma on April 1.Says on Nov. 11, 2015, Astellas and LEO Pharma entered into an Asset Purchase Agreement with regard to Astellas’ global portfolio of dermatology products, which includes the eczema treatment Protopic® (except for in Japan), and other products for the treatment of acne and skin infections.Astellas and LEO Pharma have now satisfied the pre-agreed conditions to close the transaction, with Astellas having received €675 million as a result.  Full Article

Astellas Pharma announces phase III trial of enzalutamide initiated in metastatic hormone sensitive prostate cancer
Thursday, 24 Mar 2016 09:00pm EDT 

Astellas Pharma Inc:Says the ARCHES phase III trial for enzalutamide with androgen deprivation therapy (ADT) versus placebo with ADT in metastatic hormone sensitive prostate cancer (mHSPC) patients, has been initiated.Says ARCHES means AR Inhibition with ChemoHormonal Therapy in Men with MEtastatic Castrate Sensitive Prostate Cancer.  Full Article

Astellas Pharma announces outcome of takeover bid for shares of Ocata Therapeutics
Wednesday, 10 Feb 2016 09:00am EST 

Astellas Pharma Inc:Says the company acquired 22,675,963 shares (53.6 pct stake) of Ocata Therapeutics during the period from Nov. 19, 2015 to Feb. 9 (U.S Eastern time).The company to acquire 42,331,546 shares of Ocata Therapeutics at $384 million in total.To hold 100 pct stake in Ocata Therapeutics after acquisition.  Full Article

Astellas Pharma receives sale approval for drug
Friday, 22 Jan 2016 01:00am EST 

Astellas Pharma Inc:Received sale approval for hypercholesterolemia therapeutic drug in Japan.  Full Article

Astellas Pharma announces extension of contract with Boehringer Ingelheim.
Thursday, 7 Jan 2016 04:00am EST 

Astellas Pharma Inc:Announces extension of telmisartan drugs sale contract in Japan with Boehringer Ingelheim. to March 31, 2018 from Dec. 31, 2016.  Full Article

Astellas Pharma extends offering period for shares of Ocata Therapeutics
Friday, 18 Dec 2015 04:30am EST 

Astellas Pharma Inc:Extends offering period for shares of Ocata Therapeutics, to 5pm Jan. 21, 2016 (U.S. Eastern time).  Full Article

LEO Pharma to Acquire Global Dermatology Portfolio from Astellas Pharma Inc
Wednesday, 11 Nov 2015 06:02am EST 

LEO Pharma A/S and Astellas Pharma Inc:Leo pharma to acquire global dermatology portfolio from Astellas.Says deal valued at 675 mln Euros.The transaction does not include any manufacturing facilities.Assets,associated responsibilities relating to astellas' global portfolio of dermatology products will be transferred to leo pharma.J.p. morgan is acting as financial advisor to leo pharma.  Full Article

Astellas Pharma offers takeover bid for shares of Ocata Therapeutics
Monday, 9 Nov 2015 10:00pm EST 

Astellas Pharma Inc:Astellas Pharma Inc is offering a takeover bid for 100 pct stake (or no less than 50 pct stake) of Ocata Therapeutics Inc's stock, at the price of $8.50 per share, through Astellas Pharma's U.S.-based wholly owned sub-subsidiary Laurel Acquisition Inc. (Laurel).Astellas Pharma will hold 100 pct stake in Ocata Therapeutics, up from 0 pct.Total acquisition amount is about $379 mln.Say the offering period of 20 business days from not later than Nov. 25.Says the Ocata Therapeutics to merge with Laurel and Laurel to be dissolved after the transaction.  Full Article

BRIEF-Boya Bio-Pharmaceutical plans to invest 150 mln yuan to set up buyout fund with partners

* Says it plans to invest 150 million yuan ($22.99 million) to set up buyout fund in medical industry with partners